Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023GlobeNewsWire • 07/26/23
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) LuganoGlobeNewsWire • 06/15/23
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) LuganoGlobeNewsWire • 06/09/23
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 06/03/23
Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High?Zacks Investment Research • 05/26/23
Allogene Therapeutics Announces Participation in Three Upcoming Investor ConferencesGlobeNewsWire • 05/24/23
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid CongressGlobeNewsWire • 05/11/23
Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 184.59%: Read This Before Placing a BetZacks Investment Research • 05/10/23
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/03/23
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 05/03/23
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/26/23
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023GlobeNewsWire • 04/25/23
Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 278.19%: Here's is How to TradeZacks Investment Research • 04/24/23
Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains?Zacks Investment Research • 04/24/23
Here's Why You Should Add Allogene (ALLO) Stock to Your PortfolioZacks Investment Research • 04/19/23
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/17/23